REGENERON PHARMACEUTICALS INC. - COMMON STOCK

Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD

17 сен 2025 06:30:00 Источник Nasdaq GlobeNewswire

Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation

17 сен 2025 04:00:00 Источник Nasdaq GlobeNewswire

Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer

09 сен 2025 04:00:18 Источник Nasdaq GlobeNewswire

Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

08 сен 2025 03:30:00 Источник Nasdaq GlobeNewswire

Regeneron Announces Updated Presentation Time for Upcoming Investor Conference

04 сен 2025 13:05:00 Источник Nasdaq GlobeNewswire

Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis

26 авг 2025 04:00:20 Источник Nasdaq GlobeNewswire

EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension

20 авг 2025 08:19:54 Источник Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

07 авг 2025 13:05:02 Источник Nasdaq GlobeNewswire

Regeneron Reports Second Quarter 2025 Financial and Operating Results

01 авг 2025 03:30:00 Источник Nasdaq GlobeNewswire

Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation

24 июл 2025 04:30:00 Источник Nasdaq GlobeNewswire

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

02 июл 2025 08:00:36 Источник Nasdaq GlobeNewswire

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

26 июн 2025 13:05:00 Источник Nasdaq GlobeNewswire

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

24 июн 2025 04:30:00 Источник Nasdaq GlobeNewswire

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

19 июн 2025 22:00:53 Источник Nasdaq GlobeNewswire

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

15 июн 2025 08:21:00 Источник Nasdaq GlobeNewswire

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

07 июн 2025 15:30:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

05 июн 2025 06:50:06 Источник NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

02 июн 2025 07:03:28 Источник NetDania Notify

Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist

02 июн 2025 04:05:33 Источник Nasdaq GlobeNewswire

Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass

02 июн 2025 04:00:00 Источник Nasdaq GlobeNewswire